日本局部晚期胰臟癌市场－2025-2033年

2024 年日本局部晚期胰臟癌市场规模达到 4,709 万美元，预计到 2033 年将达到 8,904 万美元，在 2025-2033 年预测期内的复合年增长率为 7.4%。

市面上局部晚期的胰臟癌（LAPC）是指疾病的一个阶段，肿瘤仍然局限于胰臟和周围区域结构，但尚未转移到远端器官，如肝臟、肺臟或远端淋巴结。在此阶段，癌症已局部扩散，并可能影响附近的关键结构，包括肠系膜上动脉或门静脉等血管，以及十二指肠、胆管和脾臟等器官。

在日本，LAPC 通常被归类为不可切除的，这意味着由于肿瘤包裹或靠近重要血管和神经，因此无法进行手术切除。在这些情况下尝试手术可能会导致严重的併发症，因此非手术治疗方式成为主要的治疗标准。

日本目前的治疗方案强调多模式方法，结合化疗（特别是 FOLFIRINOX 或吉西他滨加白蛋白结合型紫杉醇）、放射疗法、标靶疗法（例如，针对具有特定基因改变的患者的拉罗替尼、恩曲替尼）和免疫疗法（例如，针对 MSI-H/dMMR 肿瘤的派姆单抗）。

随着精准医疗的进步、生物标记驱动疗法的日益普及以及政府强有力的医疗支持，日本 LAPC 市场正在稳步增长，并为治疗创新和患者预后改善带来重大机会。

市场动态：

驾驶员和约束装置

采用标靶疗法和免疫疗法

标靶疗法和免疫疗法的日益普及代表了日本 LAPC 市场的变革驱动力，重塑了超越传统化疗的治疗模式。日本一直处于个人化肿瘤学的前沿，并得到了政府战略倡议的支持，例如 C-CAT（癌症基因组学和先进治疗中心）和 SCRUM-Japan GI-SCREEN，这是全球最大的全国性癌症基因组筛检计画之一。这些项目有助于识别胰腺癌患者中可操作的突变和生物标誌物，从而可以製定超越一刀切治疗的客製化治疗策略。

日本的医疗保健系统历来依赖 FOLFIRINOX 和吉西他滨与白蛋白结合型紫杉醇等化疗方案，现在正在迅速整合精准医疗，并得到强大的基因组检测基础设施和国家医疗保健政策的支持。标靶治疗因其能够干扰特定的癌症遗传驱动因素而得到越来越广泛的应用，例如用于治疗 BRCA 突变肿瘤的 PARP 抑制剂（例如奥拉帕尼）和用于治疗 NTRK 融合阳性癌症的 TRK 抑制剂（拉罗替尼、恩曲替尼）。

同样，获准用于治疗 MSI-H/dMMR 肿瘤的免疫疗法（如派姆单抗）也正在获得广泛应用，尤其是对于具有明确生物标记的患者而言。伴随诊断的广泛应用，加上日本国家保险系统的报销支持，使得这些疗法在各大机构中都能够得到应用。

日本胰臟学会等机构的临床指引也开始将这些治疗方法纳入实践，加速其采用。总体而言，这种向分子标靶和免疫驱动疗法的转变不仅改善了 LAPC 患者的预后，而且还推动了日本肿瘤市场的创新和成长。

延迟诊断和有限的早期检测工具

影响日本局部晚期胰腺癌 (LAPC) 市场成长和治疗成功的最重大障碍之一是由于缺乏有效的早期检测工具而导致的诊断延迟。

诊断的延迟不仅限制了手术介入的治疗窗口，而且还更依赖化疗或放疗等全身疗法，而这些疗法在延长生存期方面通常不如治癒性手术有效。从市场角度来看，这种诊断差距大大减少了适合新兴早期介入措施和新疗法的潜在患者数量。由于晚期患者需要更密集、更长的治疗，这也增加了医疗保健系统的经济负担。

因此，缺乏有效的早期检测工具和随之而来的延迟诊断对日本 LAPC 领域的临床结果和市场成长起到了关键限製作用。透过改进生物标记研究、人工智慧增强成像诊断或国家筛检计划来解决这一差距可能会改变该国胰腺癌管理的格局。

目录

第一章：市场介绍和范围

• 报告目标
• 报告范围和定义
• 报告范围

第二章：高阶主管见解与关键要点

• 市场亮点和战略要点
• 主要趋势和未来预测
• 疗法片段
• 最终用户的程式码片段

第三章：动态

• 影响因素
  • 驱动程式
    • 采用标靶疗法和免疫疗法
    • 老龄化人口中胰臟癌发生率上升
  • 限制
    • 延迟诊断和有限的早期检测工具
    • 化疗的严重副作用
  • 机会
    • 精准医疗的进展
  • 影响分析

第四章：战略洞察与产业展望

• 市场领导者和先驱者
  • 新兴先锋和杰出参与者
  • 拥有最大销售品牌的既定领导者
  • 拥有成熟产品的市场领导者
• CXO 观点
• 最新进展与突破
• 案例研究/正在进行的研究
• 监管和报销情况
• 波特五力分析
• 供应链分析
• 专利分析
• SWOT分析
• 未满足的需求和差距
• 市场进入和扩张的推荐策略
• 情境分析：最佳情况、基本情况和最坏情况预测
• 定价分析和价格动态
• 关键意见领袖

第 5 章：日本局部晚期胰臟癌市场（依疗法）

• 化疗
  • 福菲诺克斯
  • 吉西他滨
  • 白蛋白结合型紫杉醇
  • 顺铂
  • 其他的
• 手术
  • Whipple手术
  • 远端胰臟切除术
  • 全胰臟切除术
• 放射治疗
• 标靶治疗
  • 拉罗替尼
  • 恩曲替尼
• 免疫疗法

第六章：日本局部晚期胰臟癌市场（以最终用户划分）

• 医院
• 专科诊所
• 研究机构

第七章：竞争格局与市场定位

• 竞争概况和主要市场参与者
• 市占率分析与定位矩阵
• 策略伙伴关係、併购
• 产品组合和创新的关键发展
• 公司基准化分析

第八章：公司简介

• Bristol-Myers Squibb Company
• 公司概况
• 产品组合
  • 产品描述
  • 产品关键绩效指标 (KPI)
  • 历史和预测产品销售
  • 产品销售量
• 财务概览
  • 公司收入
  • 地区收入份额
  • 收入预测
• 关键进展
  • 併购
  • 关键产品开发活动
  • 监管部门批准等
• SWOT分析
• Pfizer Inc.
• Merck & Co., Inc.
• Fresenius Kabi AG
• Teva Pharmaceutical Industries Ltd
• F. Hoffmann-La Roche Ltd.
• Sun Pharmaceutical Industries Ltd.
• Merus NV
• CHEPLAPHARM Arzneimittel GmbH
• Bayer AG
• Eli Lilly and Company
• MITSUBISHI HEAVY INDUSTRIES, LTD.

第九章：假设和研究方法

• 资料收集方法
• 数据三角测量
• 预测技术
• 数据验证和确认

第 10 章：附录

The Japan locally advanced pancreatic cancer market reached US$ 47.09 million in 2024 and is expected to reach US$ 89.04 million by 2033, growing at a CAGR of 7.4% during the forecast period 2025-2033.

Locally advanced pancreatic cancer (LAPC) in the market refers to a stage of the disease where the tumor remains confined to the pancreas and surrounding regional structures but has not metastasized to distant organs such as the liver, lungs, or remote lymph nodes. At this stage, the cancer has extended locally and may involve critical nearby structures, including blood vessels like the superior mesenteric artery or portal vein, and organs such as the duodenum, bile ducts, and spleen.

In Japan, LAPC is often classified as unresectable, meaning surgical removal is not feasible due to the tumor's encasement of or proximity to vital blood vessels and nerves. Attempting surgery under these conditions may result in severe complications, which makes non-surgical treatment modalities the primary standard of care.

The current treatment landscape in Japan emphasizes a multimodal approach, combining Chemotherapy (notably FOLFIRINOX or gemcitabine plus nab-paclitaxel), radiation therapy, targeted therapy (e.g., larotrectinib, entrectinib for patients with specific genetic alterations), and immunotherapy (e.g., pembrolizumab for MSI-H/dMMR tumors).

With advancements in precision medicine, growing adoption of biomarker-driven therapies, and strong government healthcare support, the Japanese LAPC market is witnessing steady growth and holds significant opportunities for therapeutic innovation and patient outcome improvement.

Market Dynamics: Drivers & Restraints

Adoption of Targeted and Immunotherapies

The increasing adoption of targeted therapies and immunotherapies represents a transformative driver in the Japan LAPC market, reshaping the treatment paradigm beyond traditional chemotherapy. Japan has been at the forefront of personalized oncology, supported by strategic governmental initiatives such as C-CAT (Center for Cancer Genomics and Advanced Therapeutics) and SCRUM-Japan GI-SCREEN, one of the largest nationwide cancer genomic screening projects globally. These programs facilitate the identification of actionable mutations and biomarkers in pancreatic cancer patients, allowing for tailored therapeutic strategies that go beyond one-size-fits-all treatments.

Historically reliant on chemotherapy regimens like FOLFIRINOX and gemcitabine with nab-paclitaxel, the Japanese healthcare system is now rapidly integrating precision medicine, supported by robust genomic testing infrastructure and national healthcare policies. Targeted therapies, such as PARP inhibitors (e.g., olaparib) for BRCA-mutated tumors and TRK inhibitors (larotrectinib, entrectinib) for NTRK fusion-positive cancers, are being increasingly utilized due to their ability to interfere with specific genetic drivers of cancer.

Similarly, immunotherapies like pembrolizumab, approved for MSI-H/dMMR tumors, are gaining ground, particularly in patients with defined biomarkers. The widespread availability of companion diagnostics, coupled with reimbursement support from Japan's national insurance system, has made these therapies accessible across major institutions.

Clinical guidelines from bodies such as the Japan Pancreas Society have also begun incorporating these treatments into practice, accelerating their adoption. Overall, this shift toward molecularly targeted and immunologically driven therapies is not only improving the prognosis for LAPC patients but is also fueling innovation and growth in Japan's oncology market.

Delayed Diagnosis and Limited Early Detection Tools

One of the most significant barriers impacting the growth and treatment success in the Japan locally advanced pancreatic cancer (LAPC) market is the delayed diagnosis caused by the absence of effective early detection tools.

This delay in diagnosis not only limits the therapeutic window for surgical intervention but also places a heavier reliance on systemic therapies like chemotherapy or radiation, which are often less effective in prolonging survival compared to curative surgery. From a market perspective, this diagnostic gap significantly reduces the potential pool of patients eligible for emerging early-stage interventions and novel therapies. It also increases the economic burden on the healthcare system due to the need for more intensive, prolonged treatments in advanced stages.

Therefore, the lack of effective early detection tools and the consequent delayed diagnosis act as a critical restraint on both clinical outcomes and market growth in Japan's LAPC segment. Addressing this gap through improved biomarker research, AI-enhanced imaging diagnostics, or national screening programs could potentially transform the landscape of pancreatic cancer management in the country.

Segment Analysis

The Japan locally advanced pancreatic cancer market is segmented based on therapy and end-user.

Therapy:

The chemotherapy segment in the therapy is expected to dominate the Japan locally advanced pancreatic cancer market share

Chemotherapy remains the cornerstone of treatment for locally advanced pancreatic cancer (LAPC) in Japan. It works by targeting and killing rapidly dividing cells, including cancerous ones, thereby inhibiting tumor progression. Chemotherapy can be administered as monotherapy or in combination regimens, depending on the patient's performance status and clinical profile.

In Japan, the most commonly used chemotherapy agents for LAPC include Gemcitabine, FOLFIRINOX, Nab-Paclitaxel, Cisplatin, nd Others under clinical evaluation or in combination therapies. The Japan Pancreas Society (JPS) Practice Guidelines 2022 endorse FOLFIRINOX, Gemcitabine + nab-paclitaxel, and Gemcitabine monotherapy as the primary chemotherapy options for managing LAPC.

Japan's structured adherence to evidence-based treatment pathways and its high healthcare infrastructure standard have positioned chemotherapy as a critical pillar in the LAPC market. Its relatively widespread accessibility, strong clinical efficacy, and potential to convert unresectable tumors into operable cases make it a dominant therapeutic strategy.

As ongoing trials investigate newer agents and optimized combinations, chemotherapy is expected to retain its primary role in managing LAPC while evolving in precision and patient personalization.

Competitive Landscape

The major players in the Japan locally advanced pancreatic cancer market include Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co., Inc., Fresenius Kabi AG, Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd., Sun Pharmaceutical Industries Ltd., Merus N.V., CHEPLAPHARM Arzneimittel GmbH, Bayer AG, Eli Lilly and Company, MITSUBISHI HEAVY INDUSTRIES, LTD. and among others.

Key Developments

• In December 2024, Zai Lab Limited and Novocure announced positive results from the Phase 3 PANOVA-3 trial, which achieved its primary endpoint by demonstrating a statistically significant improvement in median overall survival (mOS) compared to the control group. The PANOVA-3 studies evaluated the effectiveness of Tumor Treating Fields (TTFields) therapy used in combination with gemcitabine and nab-paclitaxel as a first-line treatment for patients with unresectable, locally advanced pancreatic adenocarcinoma.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Japan locally advanced pancreatic cancer market report delivers a detailed analysis with 42 key tables, more than 25 visually impactful figures, and 136 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Application & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Therapy
• 2.4. Snippet by End-User

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Adoption of Targeted and Immunotherapies
    • 3.1.1.2. Rising Incidence of Pancreatic Cancer in an Aging Population
  • 3.1.2. Restraints
    • 3.1.2.1. Delayed Diagnosis and Limited Early Detection Tools
    • 3.1.2.2. Severe Side Effects of Chemotherapy
  • 3.1.3. Opportunity
    • 3.1.3.1. Advancements in Precision Medicine
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with the largest-selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. CXO Perspectives
• 4.3. Latest Developments and Breakthroughs
• 4.4. Case Studies/Ongoing Research
• 4.5. Regulatory and Reimbursement Landscape
• 4.6. Porter's Five Forces Analysis
• 4.7. Supply Chain Analysis
• 4.8. Patent Analysis
• 4.9. SWOT Analysis
• 4.10. Unmet Needs and Gaps
• 4.11. Recommended Strategies for Market Entry and Expansion
• 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.13. Pricing Analysis and Price Dynamics
• 4.14. Key Opinion Leaders

5. Japan Locally Advanced Pancreatic Cancer Market, By Therapy

• 5.1. Introduction
  • 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Therapy
  • 5.1.2. Market Attractiveness Index, By Therapy
• 5.2. Chemotherapy*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.2.3. Folfirinox
  • 5.2.4. Gemcitabine
  • 5.2.5. Nab-Paclitaxel
  • 5.2.6. Cisplatin
  • 5.2.7. Others
• 5.3. Surgery
  • 5.3.1. Whipple Procedure
  • 5.3.2. Distal Pancreatectomy
  • 5.3.3. Total Pancreatectomy
• 5.4. Radiation Therapy
• 5.5. Targeted Therapy
  • 5.5.1. Larotrectinib
  • 5.5.2. Entrectinib
• 5.6. Immunotherapy

6. Japan Locally Advanced Pancreatic Cancer Market, By End-User

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 6.1.2. Market Attractiveness Index, By End-User
• 6.2. Hospitals*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Specialty Clinics
• 6.4. Research Institutions

7. Competitive Landscape and Market Positioning

• 7.1. Competitive Overview and Key Market Players
• 7.2. Market Share Analysis and Positioning Matrix
• 7.3. Strategic Partnerships, Mergers & Acquisitions
• 7.4. Key Developments in Product Portfolios and Innovations
• 7.5. Company Benchmarking

8. Company Profiles

• 8.1. Bristol-Myers Squibb Company
  • 8.1.1. Company Overview
  • 8.1.2. Product Portfolio
    • 8.1.2.1. Product Description
    • 8.1.2.2. Product Key Performance Indicators (KPIs)
    • 8.1.2.3. Historic and Forecasted Product Sales
    • 8.1.2.4. Product Sales Volume
  • 8.1.3. Financial Overview
    • 8.1.3.1. Company Revenue's
    • 8.1.3.2. Geographical Revenue Shares
    • 8.1.3.3. Revenue Forecasts
  • 8.1.4. Key Developments
    • 8.1.4.1. Mergers & Acquisitions
    • 8.1.4.2. Key Product Development Activities
    • 8.1.4.3. Regulatory Approvals, etc.
  • 8.1.5. SWOT Analysis
• 8.2. Pfizer Inc.
• 8.3. Merck & Co., Inc.
• 8.4. Fresenius Kabi AG
• 8.5. Teva Pharmaceutical Industries Ltd
• 8.6. F. Hoffmann-La Roche Ltd.*
• 8.7. Sun Pharmaceutical Industries Ltd.
• 8.8. Merus N.V.
• 8.9. CHEPLAPHARM Arzneimittel GmbH
• 8.10. Bayer AG
• 8.11. Eli Lilly and Company
• 8.12. MITSUBISHI HEAVY INDUSTRIES, LTD.

LIST NOT EXHAUSTIVE

9. Assumptions and Research Methodology

• 9.1. Data Collection Methods
• 9.2. Data Triangulation
• 9.3. Forecasting Techniques
• 9.4. Data Verification and Validation

10. Appendix

• 10.1. About Us and Services
• 10.2. Contact Us